Cyclerion Therapeutics
CYCN
56 hedge funds and large institutions have $40.7M invested in Cyclerion Therapeutics in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 17 closing their positions.
553% more call options, than puts
Call options by funds: $705K | Put options by funds: $108K
0.12% less ownership
Funds ownership: 2.85% → 2.73% (-0.12%)
8% less funds holding
Funds holding: 61 → 56 (-5)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
46% less capital invested
Capital invested by funds: $75.8M → $40.7M (-$35.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.04M |
| 2 |
PVI
Pura Vida Investments
New York
|
+$825K |
| 3 |
Renaissance Technologies
New York
|
+$646K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$590K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$178K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.93M |
| 2 |
Two Sigma Investments
New York
|
-$598K |
| 3 |
D.E. Shaw & Co
New York
|
-$321K |
| 4 |
Two Sigma Advisers
New York
|
-$298K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$280K |
CYCN Hedge Fund Activity: Q4 2021 in Review
56 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q4 2021, worth a combined $40.7M — down 46% from $75.8M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CYCN and 13 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 10 added.
The largest buyer was Vanguard Group, adding an estimated $1.04M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $4.93M sold.
- 56 institutional investors held Cyclerion Therapeutics (CYCN) as of Q4 2021, down from 61 in Q3 2021.
- Funds reported $40.7M of Cyclerion Therapeutics stock for Q4 2021, down 46% quarter-over-quarter.
- 13 funds opened new Cyclerion Therapeutics positions in Q4 2021 and 17 closed out, a net change of -4 holders.
- The largest Cyclerion Therapeutics buyer in Q4 2021 was Vanguard Group, an estimated $1.04M added.
- The largest Cyclerion Therapeutics seller in Q4 2021 was EcoR1 Capital, an estimated $4.93M sold.
Based on aggregated 13F filings for Q4 2021.